Aromatase inhibitors plus metronomic capecitabine in treatment of patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Articles in Press, Accepted Manuscript, Available Online from 28 May 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2025.362240.2457 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
yosra farghaly sayed   ; Hanan Mostafa; Marwa Ismail khalaf; Aiat Morsy Mohamed Morsy
| ||||
| Clinical Oncology Department, Faculty of Medicine, Assiut University | ||||
| Abstract | ||||
| OBJECTIVES: To evaluate the efficacy and tolerability of metronomic chemotherapy plus endocrine therapy in HR+, HER2-negative metastatic breast cancer (MBC) patients. METHODS: Between August 2021 and March 2024, 40 female patient received capecitabine 500 mg PO three times per day/daily with examestane 25 mg PO once daily or letrozole 2.5 mg PO once daily. RESULTS: The clinical benefit rate (CBR) was 65.4& 35.7%% (P=0.014), median progression free survival was 18& 12 months (P=0.03), median time to progression was 13& 11.5 months (P=0.07) for first-and second-line treatment respectively. The median overall survival (OS) was 32 months (95% CI; 30.70-33.29) which was equal for first/second line therapy. Hand-foot syndrome and skin changes; grade 2 events occurred in 22.5% and grade 3-4 in 7.6% respectively. CONCLUSION: Metronomic capecitabine plus AIs showed good efficacy and well tolerated in HR+, HER2-negative MBC. Patients had CBR and long duration of first line treatment had prolonged OS. Trial registration: Clinicaltrials.gov NCT04942899 | ||||
| Keywords | ||||
| chemo endocrine; metronomic chemotherapy; aromatase inhibitors; endocrine treatment; metastatic breast cancer | ||||
|
Statistics Article View: 64 |
||||
